Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering

Rhea-AI Summary

Regentis Biomaterials (NYSE:RGNT) closed its initial public offering on December 5, 2025, selling 1,250,000 ordinary shares at $8.00 per share for aggregate gross proceeds of $10,000,000 before underwriting discounts and offering expenses. The shares began trading on the NYSE American on December 4, 2025 under the symbol RGNT. The company granted a 45-day option to purchase up to 187,500 additional shares for over-allotments.

Net proceeds are intended primarily for development activities including completion of the pivotal trial and PMA preparation for GerlinC, and for corporate purposes including repayment of certain debt and deferred compensation.

Positive

• Gross proceeds of $10,000,000 from the Offering
• Listing on NYSE American under symbol RGNT
• Underwriters granted 45-day option for 187,500 additional shares

Negative

• Stated gross proceeds exclude underwriting discounts and offering expenses
• Net proceeds will be reduced by underwriting discounts and offering expenses

Key Figures

IPO shares offered 1,250,000 Ordinary Shares Initial public offering size

IPO price $8.00 per Ordinary Share Public offering price

Gross proceeds $10,000,000 Aggregate gross proceeds before fees

Over-allotment option period 45 days Underwriters’ option duration

Over-allotment shares 187,500 Ordinary Shares Additional shares to cover over-allotments

Trading start date December 4, 2025 Ordinary Shares began trading on NYSE American

Form F-1 file number 333-285692 Registration Statement on Form F-1

F-1 effective date November 12, 2025 Form F-1 became effective, as amended

Market Reality Check

$7.49 Last Close

Volume Volume 331,227 is roughly in line with the 20-day average of 332,121 ahead of the IPO news. normal

Technical Price at $7.50 is near the reported 200-day MA of $7.50, indicating no clear pre-news trend.

Market Pulse Summary

This announcement confirms the closing of an IPO of 1,250,000 shares at $8.00 per share, raising $10,000,000 in gross proceeds. The company plans to direct funds toward completing a pivotal trial and preparing a PMA submission, while also addressing debt and deferred compensation. With no prior news history in the dataset, investors may focus on trial progress, regulatory milestones, and post-IPO trading liquidity as key metrics to watch.

Key Terms

initial public offering financial

"announced the closing of its initial public offering (the “Offering”)"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

pivotal trial medical

"primarily for development activities, including the completion of its pivotal trial"

A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.

pma submission regulatory

"preparation of the PMA submission for GerlinC, and also for corporate purposes"

A PMA submission is a formal application to the U.S. Food and Drug Administration seeking premarket approval for a high‑risk medical device by providing detailed safety and effectiveness evidence. For investors, PMA approval is a gatekeeper to commercial sales in the U.S.; receiving it can unlock significant revenue while delays, additional data requests, or rejection can push back market entry and increase development costs — think of it like applying for a very strict license to sell a new kind of vehicle.

registration statement on form f-1 regulatory

"A Registration Statement on Form F-1 (File No. 333-285692) and amendments thereto"

A registration statement on Form F-1 is a legal document companies file with regulators to offer their shares to investors in a foreign country or market. It provides essential information about the company's business, finances, and risks, helping investors make informed decisions about whether to buy its stock. This process ensures transparency and protects investors by making company details publicly available before trading begins.

prospectus regulatory

"The Offering was made only by means of a prospectus. The final prospectus was filed"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. Not financial advice.

Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 187,500 Ordinary Shares to cover over-allotments, if any.

The Ordinary Shares began trading on the NYSE American LLC on December 4, 2025, under the symbol “RGNT”.

The Company intends to use the net proceeds from the Offering primarily for development activities, including the completion of its pivotal trial, and preparation of the PMA submission for GerlinC, and also for corporate purposes including the repayment of certain debt and deferred compensation payments.

ThinkEquity acted as sole book-running manager for the Offering.

A Registration Statement on Form F-1 (File No. 333-285692) and amendments thereto relating to the Ordinary Shares sold in the Offering was filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective, as amended, on November 12, 2025. The Offering was made only by means of a prospectus. The final prospectus was filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus may also be obtained from ThinkEquity, 17 State Street, 41^st Floor, New York, New York 10004. 

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Regentis Biomaterials Ltd.

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients. The Company’s current efforts are focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue. GelrinC is Regentis’ cartilage injury therapeutic based on a unique hydrogel, erodible and resorbable, matrix of polyethylene glycol. The Company’s lead product candidate, GelrinC, is a cell-free, off-the-shelf hydrogel that is cured into a temporary implant in the knee for the treatment of painful injuries to articular knee cartilage. GelrinC was approved as a device with a Conformité Européene mark in Europe, (CE mark number 3900600CE02). The Company plans to start commercialization efforts in Europe to bring its product to market, while being focused in parallel on completing its pivotal study for obtaining United States Food and Drug Administration approval. For more information, please visit https://www.regentis.co.il/ 

Forward Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words, and include the expected use of proceeds. Forward-looking statements are based on Regentis’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting Regentis, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Regentis undertakes no duty to update such information except as required under applicable law.

For Investor Relations Inquiries

Arie Gordashnikov
arie@shimony.com
+972-3-6116629

FAQ

When did RGNT begin trading on the NYSE American and under what symbol?

RGNT began trading on December 4, 2025 on the NYSE American under the symbol RGNT.

How many shares and what price did Regentis sell in the RGNT IPO?

The company sold 1,250,000 ordinary shares at $8.00 per share for aggregate gross proceeds of $10,000,000.

What is the size of the underwriters' over-allotment option in the RGNT offering?

Underwriters received a 45-day option to purchase up to 187,500 additional ordinary shares to cover over-allotments.

How does Regentis intend to use the net proceeds from the RGNT IPO?

The company intends to use net proceeds primarily for development activities including completion of its pivotal trial and PMA preparation for GerlinC, and for corporate purposes including repayment of certain debt and deferred compensation.

Where can investors find the RGNT final prospectus filed with the SEC?

The final prospectus is available on the SEC website at www.sec.gov and copies may be obtained from ThinkEquity.